CTLA4 and acute myeloid leukemia: Notably, ICM inhibition (e.g., CTLA4, PD1) alone or in combination with HMA (Decitabine, Azacitidine) for the treatment of AML relapse after allo-HCT showed only modest results [53,54,55].